Viewing Study NCT03769467


Ignite Creation Date: 2025-12-25 @ 12:53 AM
Ignite Modification Date: 2026-01-04 @ 5:33 PM
Study NCT ID: NCT03769467
Status: TERMINATED
Last Update Posted: 2024-11-14
First Post: 2018-11-29
Is NOT Gene Therapy: True
Has Adverse Events: True

Brief Title: Tabelecleucel in Combination With Pembrolizumab in Subjects With Epstein-Barr Virus-associated Nasopharyngeal Carcinoma (EBV+ NPC)
Sponsor: Atara Biotherapeutics
Organization: